Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05635734 | Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Cantex PharmaceuticalsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03174197 | Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03277638 | Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) | completed | Phase 1 / Phase 2 | 32 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04688151 | Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. | completed | Phase 1 | 22 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05027386 | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. | completed | Phase 1 / Phase 2 | 125 | Sun Yat-sen UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03657576 | Trial of C134 in Patients With Recurrent GBM(C134-HSV-1) | completed | Phase 1 | 19 | University of Alabama at BirminghamOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT01875601 | NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | completed | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04201873 | Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | completed | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05036577 | A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL(ORMD2021) | completed | Phase 1 | 13 | Huashan HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT00911560 | Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma | completed | Phase 1 / Phase 2 | 374 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05235074 | OH2 Oncolytic Viral Therapy in Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 40 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02211768 | Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 | completed | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03030066 | Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas | completed | Phase 1 | 47 | Daiichi SankyoINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04465643 | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | completed | Phase 1 | 13 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05698199 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | completed | Phase 1 | 10 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02303678 | D2C7 for Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 81 | Darell BignerOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07198087 | A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants | completed | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT00308165 | Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors | completed | Phase 1 | 16 | Columbia UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07635173 | SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas | completed | Phase 1 | 35 | Shenzhen Zhenxing Medical Technology Co., LtdOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04911621 | Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma(ADDICT-pedGLIO) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03514069 | Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma | completed | Phase 1 | 60 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06668987 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma | completed | Phase 1 / Phase 2 | 10 | Heron Neutron Medical Corp.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT04968366 | Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery | completed | Phase 1 | 11 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03966651 | A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.(NEUROBLU 02) | completed | Phase 1 | 1 | Institut Claudius RegaudOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03154996 | Chronic Convection Enhanced Delivery of Topotecan | completed | Phase 1 | 5 | Columbia UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03451799 | Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma | completed | Phase 1 | 21 | Jethro HuOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT00083135 | N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation | completed | Phase 1 | 18 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT00093353 | N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma | completed | Phase 1 | 30 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT00295919 | N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma | completed | Phase 1 | 80 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT00509353 | N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma | completed | Phase 1 | 26 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT00646230 | N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma(IV Fenretinide) | completed | Phase 1 | 17 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 14, 2026 | clinicaltrials |
| NCT02866747 | A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma(STERIMGLI) | completed | Phase 1 / Phase 2 | 108 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07497373 | A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma(JL15003) | completed | Phase 1 | 17 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06650605 | Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma(CITADEL-123) | completed | Phase 1 | 7 | Theragnostics LtdINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04019002 | Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma | completed | Phase 1 | 17 | Susan ChangOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme(DENDR1) | completed | Phase 1 / Phase 2 | 76 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04417088 | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | completed | Phase 1 / Phase 2 | 28 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT02115074 | Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas(FLUVABREX) | completed | Phase 1 | 20 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT01165333 | Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma(CILENT) | completed | Phase 1 | 32 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04716699 | Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma | completed | Phase 1 | 12 | University of California, DavisOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03719768 | Avelumab With Radiotherapy in Patients With Leptomeningeal Disease | completed | Phase 1 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT02669173 | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | completed | Phase 1 | 12 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03429803 | DAY101 In Gliomas and Other Tumors | completed | Phase 1 | 44 | Karen D. Wright, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05938387 | Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma | completed | Phase 1 | 37 | CureVacINDUSTRY | 3 | Feb 18, 2026 | clinicaltrials |
| NCT02073994 | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | completed | Phase 1 | 174 | Institut de Recherches Internationales ServierOTHER | 2 | Feb 17, 2026 | clinicaltrials |
| NCT02481154 | Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | completed | Phase 1 | 95 | Institut de Recherches Internationales ServierOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03343197 | Study of AG-120 and AG-881 in Subjects With Low Grade Glioma | completed | Phase 1 | 49 | Institut de Recherches Internationales ServierOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03529448 | TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma(GEINOCANN) | completed | Phase 1 / Phase 2 | 33 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials